Eli Lilly's third-quarter results paint a portrait of a company riding high on the back of two blockbuster drugs—but also one that should worry investors focused on long-term growth. Yes, Mounjaro and Zepbound delivered spectacular numbers, with Mounjaro's worldwide revenue rising 65% to $10.72 billion and Zepbound posting $5.35 billion in sales. The stock rose about 7% on Thursday, and the company hiked its 2026 revenue guidance to between $91 billion and $92 billion, up from $85 billion to $87 billion. But buried in these headlines is a troubling reality: Foundayo, Lilly's newly launched obesity pill, missed Wall Street expectations with just $184 million in sales for the third quarter, falling short of the estimated $229 million forecast.
This Foundayo shortfall matters because it exposes a critical vulnerability in Lilly's growth narrative. CEO Dave Ricks told CNBC that he estimates only 3% to 10% of eligible patients access obesity care in the U.S., suggesting "room for expansion here of this market is dramatic." But if Lilly can't fully capitalize on oral medication uptake—an easier delivery method than injections for many patients—the company's ability to expand that addressable market is less certain than the rosy guidance suggests. The pill, which won U.S. approval in April, took in $184 million when analysts expected $229 million, and even though Lilly CFO Lucas Montarces noted that total U.S. prescriptions for Foundayo doubled from the previous quarter, this still represents underperformance in a category where Lilly should dominate.
The market share numbers also tell a cautionary tale. While Lilly holds 63% of the U.S. obesity and diabetes drug market in the third quarter compared to Novo's 36.6%, these injectable-driven figures mask Foundayo's competitive reality. Montarces said that around 4 in 10 patients starting an oral obesity medicine choose Foundayo, meaning Novo is capturing 6 in 10. That's not dominance—that's a coin flip. If Lilly cannot decisively win the oral category as the market diversifies away from injections, the company's market share lead could erode faster than current guidance assumes.
There's another complication: lower net prices. While volume surged 41% in the U.S., realized prices dropped 7%, primarily from Zepbound. Internationally, prices fell 29% despite a 76% volume increase. These discounts are masking the reality that Lilly is growing revenue primarily through volume expansion, not pricing power. Eventually, volume growth plateaus, and when it does, Lilly will need pricing leverage it no longer possesses.
Lilly's massive 2026 guidance upgrade and aggressive deal-making spree—including the Merida Biosciences acquisition—suggests the company is confident in sustaining this momentum. But the Foundayo miss suggests otherwise. Until Lilly can prove it can win decisively in the oral GLP-1 category and maintain pricing discipline, investors should temper their enthusiasm about the "dramatic" market expansion Ricks envisions. Sometimes the most important signal is what a company fails to hit, not what it exceeds.